New intranasal and injectable gene therapy for healthy life extension.
Level 5 - mechanism / opinion, no new human data
Preclinical animal research with no human data; retracted publication
PubMed 35537048 · doi:10.1073/pnas.2121499119
What was done
The authors evaluated high-capacity mouse cytomegalovirus (MCMV) vectors delivering exogenous telomerase reverse transcriptase (TERT) or follistatin (FST) via intranasal and injectable routes in mice. They assessed median lifespan, glucose tolerance, physical performance, body mass loss, alopecia, telomere length, and mitochondrial structural preservation across multiple organs.
What was found
MCMV-TERT and MCMV-FST extended median lifespan in mice by 41.4% and 32.5%, respectively. Both delivery routes improved glucose tolerance and physical performance while preventing body mass loss and alopecia. Telomere shortening was ameliorated by TERT, and both treatments halted mitochondrial deterioration without reported carcinogenicity or side effects. Intranasal and injectable delivery performed equally well across organs. No exact sample sizes, variance measures, or p-values were reported in the abstract.
Why it matters
The study demonstrated that cytomegalovirus vectors could serve as an intranasal or injectable platform to deliver longevity-associated genes across multiple organs in mice.
Limits
The study was conducted entirely in animal models with no human data, and the abstract omits sample sizes, exact dosages, and variance metrics. Crucially, the record indicates this is a retracted publication.
Cited by
- contradicts Gene therapies using follistatin and telomerase reproducibly improve hallmarks, biomarkers, and diseases of aging across mouse models.
- context Follistatin and TERT gene therapy treatments produced a statistically significant longevity extension in rodents.